APA

Nolte F., Höchsmann B., Giagounidis A., Lübbert M., Platzbecker U., Haase D., Lück A., Gattermann N., Taupitz M., Baier M., Leismann O., Junkes A., Schumann C., Hofmann W. K. & Schrezenmeier H. (20130307). Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. : Annals of hematology.

Chicago

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann W K and Schrezenmeier H. 20130307. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. : Annals of hematology.

Harvard

Nolte F., Höchsmann B., Giagounidis A., Lübbert M., Platzbecker U., Haase D., Lück A., Gattermann N., Taupitz M., Baier M., Leismann O., Junkes A., Schumann C., Hofmann W. K. and Schrezenmeier H. (20130307). Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. : Annals of hematology.

MLA

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann W K and Schrezenmeier H. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. : Annals of hematology. 20130307.